Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise based in Melbourne, Australia, filed this Form 6-K for the month of June 2026. The report is incorporated by reference into various Registration Statements on Forms S-8 and F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory updates rather than financial performance data.
Material Changes
The primary material change disclosed is a "Change in substantial holding," submitted as Exhibit 99.1. No other material changes to operations or financial status are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves strictly to report the change in substantial holding and update registration statements.
Investor Verification Checklist
- Verify the details of the "Change in substantial holding" referenced in Exhibit 99.1.
- Confirm the impact of this holding change on the company's registration statements (Forms S-8 and F-3).
- Review the company's most recent Form 20-F for comprehensive financial data, as this 6-K does not contain financial statements.